These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 11862582)

  • 21. Polymorphisms in the angiotensinogen and angiotensin II type 1 receptor gene are related to change in left ventricular mass during antihypertensive treatment: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial.
    Kurland L; Melhus H; Karlsson J; Kahan T; Malmqvist K; Ohman P; Nyström F; Hägg A; Lind L
    J Hypertens; 2002 Apr; 20(4):657-63. PubMed ID: 11910301
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Eprosartan improves cardiac performance, reduces cardiac hypertrophy and mortality and downregulates myocardial monocyte chemoattractant protein-1 and inflammation in hypertensive heart disease.
    Behr TM; Willette RN; Coatney RW; Berova M; Angermann CE; Anderson K; Sackner-Bernstein JD; Barone FC
    J Hypertens; 2004 Mar; 22(3):583-92. PubMed ID: 15076165
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension.
    Thürmann PA; Kenedi P; Schmidt A; Harder S; Rietbrock N
    Circulation; 1998 Nov; 98(19):2037-42. PubMed ID: 9808602
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ME3221, a surmountable angiotensin AT1-receptor antagonist, prevents hypertensive complications in aged stroke-prone spontaneously hypertensive rats.
    Nagura J; Hui C; Yamamoto M; Yasuda S; Abe M; Hachisu M; Konno F
    Jpn J Pharmacol; 1996 May; 71(1):39-49. PubMed ID: 8791170
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative effects of chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade on cardiac remodeling after myocardial infarction in the rat.
    Schieffer B; Wirger A; Meybrunn M; Seitz S; Holtz J; Riede UN; Drexler H
    Circulation; 1994 May; 89(5):2273-82. PubMed ID: 8181153
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reduction of development of left ventricular hypertrophy in salt-loaded Dahl salt-sensitive rats by angiotensin II receptor inhibition.
    de Simone G; Devereux RB; Camargo MJ; Wallerson DC; Sealey JE; Laragh JH
    Am J Hypertens; 1996 Mar; 9(3):216-22. PubMed ID: 8695019
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension.
    Gottdiener JS
    Circulation; 1999 Aug; 100(6):685-6. PubMed ID: 10490345
    [No Abstract]   [Full Text] [Related]  

  • 28. Advanced hypertensive heart disease in spontaneously hypertensive rats. Lisinopril-mediated regression of myocardial fibrosis.
    Brilla CG; Matsubara L; Weber KT
    Hypertension; 1996 Aug; 28(2):269-75. PubMed ID: 8707393
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of an AT1 receptor antagonist, an ACE inhibitor and a calcium channel antagonist on cardiac gene expressions in hypertensive rats.
    Kim S; Ohta K; Hamaguchi A; Yukimura T; Miura K; Iwao H
    Br J Pharmacol; 1996 Jun; 118(3):549-56. PubMed ID: 8762077
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Improvement in the capillarity of the left ventricular wall of stroke-prone spontaneously hypertensive rats following angiotensin II receptor blockade.
    Xie Z; Gao M; Togashi H; Saito H; Koyama T
    Clin Exp Hypertens; 1999 May; 21(4):441-52. PubMed ID: 10369385
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Losartan and the LIFE-study. Antihypertensive treatment with AT1-receptor antagonist].
    Kjeldsen SE; Omvik P
    Tidsskr Nor Laegeforen; 1996 Feb; 116(4):504-7. PubMed ID: 8644056
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aldosterone breakthrough during angiotensin II receptor antagonist therapy in stroke-prone spontaneously hypertensive rats.
    Naruse M; Tanabe A; Sato A; Takagi S; Tsuchiya K; Imaki T; Takano K
    Hypertension; 2002 Jul; 40(1):28-33. PubMed ID: 12105134
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chronic angiotensin II type 1 receptor antagonism in genetic hypertension: effects on vascular structure and reactivity.
    Oddie CJ; Dilley RJ; Kanellakis P; Bobik A
    J Hypertens; 1993 Jul; 11(7):717-24. PubMed ID: 8228190
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tissue velocity echocardiography shows early improvement in diastolic function with irbesartan and atenolol therapy in patients with hypertensive left ventricular hypertrophy. Results form the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA).
    Müller-Brunotte R; Kahan T; Malmqvist K; Ring M; Edner M
    Am J Hypertens; 2006 Sep; 19(9):927-36. PubMed ID: 16942935
    [TBL] [Abstract][Full Text] [Related]  

  • 35. p38 MAP kinase activity is correlated with angiotensin II type 1 receptor blocker-induced left ventricular reverse remodeling in spontaneously hypertensive heart failure rats.
    Liang Q; Elson AC; Gerdes AM
    J Card Fail; 2006 Aug; 12(6):479-86. PubMed ID: 16911916
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of the structural modification of Candesartan with Zinc on hypertension and left ventricular hypertrophy.
    Martinez VR; Martins Lima A; Stergiopulos N; Velez Rueda JO; Islas MS; Griera M; Calleros L; Rodriguez Puyol M; Jaquenod de Giusti C; Portiansky EL; Ferrer EG; De Giusti V; Williams PAM
    Eur J Pharmacol; 2023 May; 946():175654. PubMed ID: 36930883
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Regression of left ventricular hypertrophy in human hypertension with irbesartan.
    Malmqvist K; Kahan T; Edner M; Held C; Hägg A; Lind L; Müller-Brunotte R; Nyström F; Ohman KP; Osbakken MD; Ostergern J
    J Hypertens; 2001 Jun; 19(6):1167-76. PubMed ID: 11403367
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term treatment of spontaneously hypertensive rats with PD123319 and electrophysiological remodeling of left ventricular myocardium.
    Ying X; Kai-Pan G; Wei-Qing L; Long-Yun P; De-Xi W; Zhi-Bin H
    Naunyn Schmiedebergs Arch Pharmacol; 2016 Dec; 389(12):1333-1340. PubMed ID: 27629578
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of angiotensin II and bradykinin on aortic collagen following converting enzyme inhibition in spontaneously hypertensive rats.
    Benetos A; Levy BI; Lacolley P; Taillard F; Duriez M; Safar ME
    Arterioscler Thromb Vasc Biol; 1997 Nov; 17(11):3196-201. PubMed ID: 9409311
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Experimental evidence for effects of ramipril on cardiac and vascular hypertrophy beyond blood pressure reduction.
    Linz W; Gohlke P; Unger T; Schölkens BA
    Arch Mal Coeur Vaiss; 1995 Feb; 88 Spec No 2():31-4. PubMed ID: 7646309
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.